ArticleAntimicrobial agents and chemotherapy2019
Dual Role of
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- The therapeutic potential of phage pT2784 against ST40-KL47 typeMicrobiology spectrum · 2026Article
- PiuA promoter mutations confer cefiderocol resistance inFrontiers in microbiology · 2026Article
- Discovery of novel BfmR inhibitors restoring carbapenem susceptibility against carbapenem-resistantEmerging microbes & infections · 2024Article
- The tigecycline resistance mechanisms in Gram-negative bacilli.Frontiers in cellular and infection microbiology · 2024Review
- Review
- Virulence Factors and Pathogenicity Mechanisms ofAntibiotics (Basel, Switzerland) · 2023Review
- Mutation in the two-component regulator BaeSR mediates cefiderocol resistance and enhances virulence inmSystems · 2023Article
- Alteration ofMicrobiology spectrum · 2023Article
- Resistance mechanisms of tigecycline inFrontiers in cellular and infection microbiology · 2023Review
- Structural Basis of PER-1-Mediated Cefiderocol Resistance and Synergistic Inhibition of PER-1 by Cefiderocol in Combination with Avibactam or Durlobactam in Acinetobacter baumannii.Antimicrobial agents and chemotherapy · 2022Article
- Interactions between host epithelial cells andEmerging microbes & infections · 2022Article
- Description of a Rare Pyomelanin-Producing Carbapenem-Resistant Acinetobacter baumannii Strain Coharboring Chromosomal OXA-23 and NDM-1.Microbiology spectrum · 2022Article
- Phenotypic and Genotypic Characterization of a Hypervirulent Carbapenem-Resistant Klebsiella pneumoniae ST17-KL38 Clinical Isolate Harboring the Carbapenemase IMP-4.Microbiology spectrum · 2022Article
- Deciphering the genetic network and programmed regulation of antimicrobial resistance in bacterial pathogens.Frontiers in cellular and infection microbiology · 2022Review
- Tigecycline Suppresses the Virulence Factors of Multidrug-ResistantInfection and drug resistance · 2022Article
- Colistin-phage combinations decrease antibiotic resistance inEmerging microbes & infections · 2021Article
- Novel tigecycline resistance mechanisms inEmerging microbes & infections · 2021Article
- Review
- The mismatch repair system (mutS and mutL) in Acinetobacter baylyi ADP1.BMC microbiology · 2020Article
- Recent Advances in Genetic Tools forFrontiers in genetics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.